Domača stranCMPS • NASDAQ
add
Compass Pathways PLC
3,67 $
Po zaprtju:(2,18 %)+0,080
3,75 $
Konec trgovanja: 3. mar., 16:04:27 GMT -5 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
3,93 $
Dnevni razpon
3,66 $ - 4,10 $
Letni razpon
3,17 $ - 12,57 $
Tržna kapitalizacija
339,20 mio. USD
Povprečni obseg
1,18 mio.
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | dec. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | — | — |
Stroški poslovanja | 38,21 mio. | 9,02 % |
Čisti dohodek | −43,33 mio. | −33,20 % |
Čista dobičkovnost prihodkov | — | — |
Earnings per share | −0,63 | −18,87 % |
EBITDA | −38,16 mio. | −9,06 % |
Efektivna davčna stopnja | −2,42 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | dec. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 165,08 mio. | −25,03 % |
Skupna sredstva | 213,67 mio. | −22,58 % |
Skupne obveznosti | 58,97 mio. | 17,37 % |
Celoten lastniški kapital | 154,70 mio. | — |
Shares outstanding | 92,67 mio. | — |
Razmerje P/B | 1,74 | — |
Donosnost sredstev | −41,44 % | — |
Donosnost kapitala | −46,32 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | dec. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −43,33 mio. | −33,20 % |
Denar iz dejavnosti | −41,76 mio. | −50,30 % |
Denar iz naložb | — | — |
Denar iz financiranja | 155,00 tis. | 278,05 % |
Neto sprememba denarnih sredstev | −41,87 mio. | −50,99 % |
Prost denarni tok | −44,04 mio. | −133,07 % |
Vizitka
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wikipedia
Datum ustanovitve
13. jun. 2016
Spletno mesto
Zaposleni
166
